Cryoport, Inc. (NASDAQ:CYRX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $12.29.

Several equities research analysts recently weighed in on CYRX shares. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Cryoport in a research note on Friday, January 17th. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a "buy" rating and a $11.00 target price for the company. UBS Group lifted their price objective on Cryoport from $7.00 to $9.00 and gave the company a "neutral" rating in a research report on Friday, October 18th. Finally, Roth Mkm dropped their target price on shares of Cryoport from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, November 8th.

Insider Buying and Selling at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares of the company's stock, valued at $443,847.62. The trade was a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the transaction, the chief executive officer now directly owns 731,897 shares in the company, valued at $4,764,649.47. The trade was a 6.39 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,869 shares of company stock worth $735,673. Company insiders own 10.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CYRX. Fred Alger Management LLC grew its holdings in shares of Cryoport by 49.9% in the 3rd quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company's stock valued at $21,887,000 after buying an additional 898,481 shares during the period. Thematics Asset Management grew its stake in Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company's stock valued at $13,828,000 after acquiring an additional 1,087,800 shares during the period. Geode Capital Management LLC grew its stake in Cryoport by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company's stock valued at $8,902,000 after acquiring an additional 38,520 shares during the period. State Street Corp increased its holdings in shares of Cryoport by 2.8% in the third quarter. State Street Corp now owns 1,003,080 shares of the company's stock worth $8,135,000 after acquiring an additional 27,438 shares in the last quarter. Finally, AXA S.A. raised its position in shares of Cryoport by 274.2% during the second quarter. AXA S.A. now owns 873,217 shares of the company's stock worth $6,034,000 after purchasing an additional 639,855 shares during the period. Institutional investors and hedge funds own 92.90% of the company's stock.

Cryoport Stock Performance

Cryoport stock traded up $0.41 on Wednesday, reaching $8.57. 455,474 shares of the stock were exchanged, compared to its average volume of 309,244. The stock has a market cap of $423.62 million, a PE ratio of -2.54 and a beta of 1.58. The firm has a fifty day moving average price of $7.70 and a two-hundred day moving average price of $7.90. Cryoport has a twelve month low of $5.32 and a twelve month high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.23. The company had revenue of $56.66 million for the quarter, compared to the consensus estimate of $58.13 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period in the previous year, the business posted ($0.31) EPS. Sell-side analysts anticipate that Cryoport will post -0.99 EPS for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.